High‐dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China

High‐dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China

Abstract The purpose of this retrospective study was to compare the efficacy and toxicity of high‐dose methotrexate plus temozolomide (MT regimen) and rituximab plus MT (RMT regimen) in patients with untreated primary central nervous system lymphoma (PCNSL). A total of 62 patients with untreated PCN...

Full description

Bibliographic Details
Main Authors: Cui Chen, Peng Sun, Juan Cui, Shumei Yan, Hao Chen, Yi Xia, Xiwen Bi, Panpan Liu, Yu Wang, Hang Yang, Man Nie, Xue‐Wen Zhang, Wenqi Jiang, Zhi‐Ming Li
Format: Article
Language:English
Published: Wiley 2019-04-01
Series:Cancer Medicine
Subjects:
chemotherapy
high‐dose methotrexate (HD‐MTX)
primary central nervous system lymphoma (PCNSL)
rituximab
temozolomide (TMZ)
Online Access:https://doi.org/10.1002/cam4.1906

Internet

https://doi.org/10.1002/cam4.1906

Similar Items